|Bid||927,000.00 x 0|
|Ask||928,000.00 x 0|
|Day's Range||907,000.00 - 938,000.00|
|52 Week Range||624,000.00 - 948,000.00|
|Beta (5Y Monthly)||0.80|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 19, 2021 - Oct 25, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||499,500.00|
Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization, today announced strong financial results for the second quarter of fiscal 2021.
Samsung Biologics (KRX: 207940.KS), one of the world's leading contract development and manufacturing organization (CDMO), signed a strategic partnership agreement with Kineta, Inc., a clinical-stage biotech company developing novel immunotherapies in oncology. Samsung Biologics will provide end-to-end CDMO service from cell line development, clinical drug substance, and drug product manufacturing services to support IND filing for KVA12.1, Kineta's novel anti-VISTA antibody in development for t
Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization (CDMO), published its first annual sustainability report, consolidating the company's policies for an enhanced ESG management system and related plans. The report focuses on the company's commitment to taking part in social responsibility over the past decade and its future plans for the next ten years and beyond.